Comparing first- and multiple episode completers, using the severity remission criteria only, first-episode patients display higher remission frequencies during follow-up (61% vs 52%). Comparing first- and multiple episode completers,

using the severity and time remission criteria, first-episode patients display Inhibitors,research,lifescience,medical higher remission frequencies during follow-up (48% vs 43%). In approximately 75% of patients who reached remission (severity only or severity and time) at some point during follow-up remission remains stable. Remission frequencies are higher in patients completing the follow-up assessments compared to patients who dropped out of the study/treatment. Table III. Remission frequencies (in %) over various follow-up time-points

in first- and multiple-episode patients (sorted according to duration of trial). LOCF = Last-observation-carried-forward; CO = Completers only; NS = Not specified. (1) Stability of remission … Predictors of remission Attempts have been made to Inhibitors,research,lifescience,medical identify predictors of treatment outcome in schizophrenia since the introduction of effective treatment more than 50 years ago.51 With respect to remission, Inhibitors,research,lifescience,medical identification of specific premorbid, demographic, early improvement, and treatment predictors could help to identify patients who will possibly achieve remission and to identify risk factors for nonremission. With respect to the proposed Inhibitors,research,lifescience,medical remission criteria, 12 studies to date have assessed predictors of remission using multivariate regression models (Table

IV). Multivariate regression takes into account several predictive variables simultaneously and controls for confounders, thus modeling the predictive value of interest with higher accuracy than univariate analyses. Overall, 6 most relevant Inhibitors,research,lifescience,medical predictors of symptomatic remission were identified (Table IV): (i) shorter duration of untreated psychosis (assessed in 6 of 12 studies, in 5 of 6 studies being a significant predictor of remission [SPR]); (ii) better premorbid adjustment (assessed in 5 of 12 studies, in 4 of 5 studies SPR); (iii) lower psychopathology or illness severity scores at baseline (assessed in 11 of 12 studies, in 10 of 12 studies SPR); (iv) Fossariinae better functioning level at baseline (assessed in 9 of 12 studies, in 7 of 9 studies SPR); (v) early improvement in symptoms or functioning (assessed in 7 of 12 studies, in 5 of 5 studies SPR); and (vi) medication adherence during treatment (assessed in 4 of 12 studies, in 3 of 4 studies SPR). Two other predictors were less clear AZD8055 related to remission: (i) female gender (assessed in 11 of 12 studies, in 2 of 11 studies SPR); and (ii) lack of substance use disorder at baseline or persistent substance use during treatment (assessed in 6 of 12 studies, in only 3 of 6 studies SPR).